Free tool
FAERS Monitor: Avycaz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206494 or its brand name (Avycaz, Avibactam Sodium, Ceftazidime). Reports on generic versions are filed under their own applications.
Reports
169
Serious
72
43% of reports
Hospitalization
33
Death reported
16
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use34
- product storage error15
- drug resistance12
- respiratory failure9
- acute kidney injury8
- hypotension7
- mental status changes7
- pyrexia7
- death6
- dyspnoea6
- headache6
- nausea6
- drug ineffective5
- pneumonia5
- abdominal pain4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 15 |
| 2016 | 22 |
| 2017 | 19 |
| 2018 | 11 |
| 2019 | 26 |
| 2020 | 14 |
| 2021 | 11 |
| 2022 | 10 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 14 |
| 2026 | 15 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,990 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug resistanceSignal | 12 | 58.2 | 33.7 | 619 |
| mental status changesSignal | 7 | 31.4 | 15.2 | 177 |
| product storage errorSignal | 15 | 21.3 | 13.2 | 272 |
| respiratory failureSignal | 9 | 15.4 | 8.1 | 107 |
| acute kidney injurySignal | 8 | 6.5 | 3.3 | 32 |
| off label useSignal | 34 | 4.8 | 3.6 | 104 |
| hypotensionSignal | 7 | 4.3 | 2.1 | 15 |
| pyrexiaSignal | 7 | 2.5 | 1.2 | 5 |
| abdominal pain | 4 | 2.1 | 0.8 | 1 |
| pneumonia | 5 | 1.9 | 0.8 | 1 |
| dyspnoea | 6 | 1.3 | 0.6 | 0 |
| headache | 6 | 1.2 | 0.5 | 0 |
| nausea | 6 | 0.9 | 0.4 | 0 |
| death | 6 | 0.9 | 0.4 | 0 |
| drug ineffective | 5 | 0.5 | 0.2 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.